New antituberculous drugs derived from natural products: current perspectives and issues in antituberculous drug development

The cursed duet today: Tuberculosis and HIV-coinfection

(2017) Simon Tiberi et al.   PRESSE MEDICALE

Sansanmycin natural product analogues as potent and selective anti-mycobacterials that inhibit lipid I biosynthesis

(2017) Anh T. Tran et al.   Nature Communications

Tuberculosis — drugs in the 2016 development pipeline

(2017) Barbara E. Laughon et al.   Nature Reviews Disease Primers

Discovery of Novel Oral Protein Synthesis Inhibitors of Mycobacterium tuberculosis That Target Leucyl-tRNA Synthetase

(2016) Andrés Palencia et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Development of new antituberculosis drugs from natural products

(2016) Masayuki Igarashi   BIOSCIENCE BIOTECHNOLOGY AND BIOCHEMISTRY

TB Alliance regimen development for multidrug-resistant tuberculosis

(2016) S. Murray et al.   INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE

Challenges facing the drug discovery pipeline for non-tuberculous mycobacteria

(2016) Isha Soni et al.   JOURNAL OF MEDICAL MICROBIOLOGY

A Phase 2 Randomized Trial of a Rifapentine plus Moxifloxacin-Based Regimen for Treatment of Pulmonary Tuberculosis

(2016) Marcus B. Conde et al.   PLoS One

Management of multidrug-resistant TB: novel treatments and their expansion to low resource settings

(2016) Derek J. Sloan et al.   TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE

The pharmacological challenges of treating tuberculosis and HIV coinfections

(2016) Eric F. Egelund et al.   Expert Review of Clinical Pharmacology

Tuberculosis

(2016) Madhukar Pai et al.   Nature Reviews Disease Primers

Mode of Action of Clofazimine and Combination Therapy with Benzothiazinones against Mycobacterium tuberculosis

(2015) Benoit Lechartier et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Isolation and Characterization of a Hybrid Respiratory Supercomplex Consisting ofMycobacterium tuberculosisCytochromebccandMycobacterium smegmatisCytochromeaa3

(2015) Mi-Sun Kim et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Origins of the Quinolone Class of Antibacterials: An Expanded “Discovery Story”

(2015) Gregory S. Bisacchi   JOURNAL OF MEDICINAL CHEMISTRY

Hit and lead criteria in drug discovery for infectious diseases of the developing world

(2015) Kei Katsuno et al.   NATURE REVIEWS DRUG DISCOVERY

Targeting DnaN for tuberculosis therapy using novel griselimycins

(2015) A. Kling et al.   SCIENCE

Cutaneous tuberculosis overview and current treatment regimens

(2015) Lindi van Zyl et al.   TUBERCULOSIS

Latent tuberculosis infection – Revisiting and revising concepts

(2015) Padmini Salgame et al.   TUBERCULOSIS

Energy Metabolism and Drug Efflux in Mycobacterium tuberculosis

(2014) P. A. Black et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Population Pharmacokinetic/Pharmacodynamic Analysis of the Bactericidal Activities of Sutezolid (PNU-100480) and Its Major Metabolite against Intracellular Mycobacterium tuberculosis inEx VivoWhole-Blood Cultures of Patients with Pulmonary Tuberculosis

(2014) Tong Zhu et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Phase I Safety, Pharmacokinetics, and Pharmacogenetics Study of the Antituberculosis Drug PA-824 with Concomitant Lopinavir-Ritonavir, Efavirenz, or Rifampin

(2014) Kelly E. Dooley et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

The Cyclic Peptide Ecumicin Targeting ClpC1 Is Active against Mycobacterium tuberculosis In Vivo

(2014) Wei Gao et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Delamanid Does Not Inhibit or Induce Cytochrome P450 Enzymes in Vitro

(2014) Yoshihiko Shimokawa et al.   BIOLOGICAL & PHARMACEUTICAL BULLETIN

Principles for designing future regimens for multidrug-resistant tuberculosis

(2014) Grania Brigden et al.   BULLETIN OF THE WORLD HEALTH ORGANIZATION

Lassomycin, a Ribosomally Synthesized Cyclic Peptide, Kills Mycobacterium tuberculosis by Targeting the ATP-Dependent Protease ClpC1P1P2

(2014) Ekaterina Gavrish et al.   CHEMISTRY & BIOLOGY

Mycolic Acids: Structures, Biosynthesis, and Beyond

(2014) Hedia Marrakchi et al.   CHEMISTRY & BIOLOGY

Treatment Optimization in Patients Co-Infected with HIV and Mycobacterium tuberculosis Infections: Focus on Drug–Drug Interactions with Rifamycins

(2014) Mario Regazzi et al.   CLINICAL PHARMACOKINETICS

Inhaled antibiotics: dry or wet?

(2014) H. A. W. M. Tiddens et al.   EUROPEAN RESPIRATORY JOURNAL

Bedaquiline: a review of human pharmacokinetics and drug-drug interactions

(2014) R. P. G. van Heeswijk et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Multitarget Drug Discovery for Tuberculosis and Other Infectious Diseases

(2014) Kai Li et al.   JOURNAL OF MEDICINAL CHEMISTRY

Spectinamides: a new class of semisynthetic antituberculosis agents that overcome native drug efflux

(2014) Richard E Lee et al.   NATURE MEDICINE

High-Dose Rifapentine with Moxifloxacin for Pulmonary Tuberculosis

(2014) Amina Jindani et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mycobactericidal Activity of Sutezolid (PNU-100480) in Sputum (EBA) and Blood (WBA) of Patients with Pulmonary Tuberculosis

(2014) Robert S. Wallis et al.   PLoS One

Delivery of Aerosolized Liposomal Amikacin as a Novel Approach for the Treatment of Nontuberculous Mycobacteria in an Experimental Model of Pulmonary Infection

(2014) Sasha J. Rose et al.   PLoS One

Syntheses and Antituberculosis Activity of 1,3-Benzothiazinone Sulfoxide and Sulfone Derived from BTZ043

(2014) Rohit Tiwari et al.   ACS Medicinal Chemistry Letters

Nanotechnology and pulmonary delivery to overcome resistance in infectious diseases

(2013) Fernanda Andrade et al.   ADVANCED DRUG DELIVERY REVIEWS

Comparison of Levofloxacin versus Moxifloxacin for Multidrug-Resistant Tuberculosis

(2013) Won-Jung Koh et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Phase I, Single-Dose, Dose-Escalating Study of Inhaled Dry Powder Capreomycin: a New Approach to Therapy of Drug-Resistant Tuberculosis

(2013) Ashwin S. Dharmadhikari et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Progress in targeting cell envelope biogenesis inMycobacterium tuberculosis

(2013) Mary Jackson et al.   Future Microbiology

Novel semisynthetic antibiotics from caprazamycins A–G: caprazene derivatives and their antibacterial activity

(2013) Yoshiaki Takahashi et al.   JOURNAL OF ANTIBIOTICS

Structural Basis of Mycobacterial Inhibition by Cyclomarin A

(2013) Dileep Vasudevan et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Inhibition of the First Step in Synthesis of the Mycobacterial Cell Wall Core, Catalyzed by the GlcNAc-1-phosphate Transferase WecA, by the Novel Caprazamycin Derivative CPZEN-45

(2013) Yoshimasa Ishizaki et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis

(2013) Kevin Pethe et al.   NATURE MEDICINE

Advances in the development of new tuberculosis drugs and treatment regimens

(2013) Alimuddin Zumla et al.   NATURE REVIEWS DRUG DISCOVERY

Nontuberculous mycobacterial (NTM) lung disease: The top ten essentials

(2013) Timothy R. Aksamit et al.   RESPIRATORY MEDICINE

Approval of Novel TB Drug Celebrated--With Restraint

(2013) J. Cohen   SCIENCE

Phase II studies of nebulised Arikace in CF patients withPseudomonas aeruginosainfection

(2013) J P Clancy et al.   THORAX

SQ109 Targets MmpL3, a Membrane Transporter of Trehalose Monomycolate Involved in Mycolic Acid Donation to the Cell Wall Core of Mycobacterium tuberculosis

(2012) Kapil Tahlan et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Pharmacokinetics of Sequential Doses of Capreomycin Powder for Inhalation in Guinea Pigs

(2012) L. Garcia-Contreras et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Controlled-release approaches towards the chemotherapy of tuberculosis

(2012) Bullo Saifullah et al.   International Journal of Nanomedicine

Natural Products As Sources of New Drugs over the 30 Years from 1981 to 2010

(2012) David J. Newman et al.   JOURNAL OF NATURAL PRODUCTS

Race heats up for first-to-market drugs for resistant tuberculosis

(2012) Cassandra Willyard   NATURE MEDICINE

The Natural Product Cyclomarin Kills Mycobacterium Tuberculosis by Targeting the ClpC1 Subunit of the Caseinolytic Protease

(2011) Esther K. Schmitt et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

Clofazimine Analogs with Efficacy against Experimental Tuberculosis and Reduced Potential for Accumulation

(2011) Yu Lu et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

BAY41-6551 achieves bactericidal tracheal aspirate amikacin concentrations in mechanically ventilated patients with Gram-negative pneumonia

(2011) Michael S. Niederman et al.   INTENSIVE CARE MEDICINE

Tuberculosis

(2011) Stephen D Lawn et al.   LANCET

Nitazoxanide Disrupts Membrane Potential and Intrabacterial pH Homeostasis of Mycobacterium tuberculosis

(2011) Luiz Pedro S. de Carvalho et al.   ACS Medicinal Chemistry Letters

High-Resolution Phenotypic Profiling Defines Genes Essential for Mycobacterial Growth and Cholesterol Catabolism

(2011) Jennifer E. Griffin et al.   PLoS Pathogens

In Vitro Interactions between New Antitubercular Drug Candidates SQ109 and TMC207

(2010) V. M. Reddy et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Acyldepsipeptide Antibiotics Induce the Formation of a Structured Axial Channel in ClpP: A Model for the ClpX/ClpA-Bound State of ClpP

(2010) Dominic Him Shun Li et al.   CHEMISTRY & BIOLOGY

Reduction of Clofazimine by Mycobacterial Type 2 NADH:Quinone Oxidoreductase

(2010) Takahiro Yano et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

The structures of the anti-tuberculosis antibiotics viomycin and capreomycin bound to the 70S ribosome

(2010) Robin E Stanley et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

Efficacy and Safety of Inhaled Aztreonam Lysine for Airway Pseudomonas in Cystic Fibrosis

(2009) George Z. Retsch-Bogart et al.   CHEST

Cryptosporidium and Giardia: Treatment options and prospects for new drugs

(2009) Jean-François Rossignol   EXPERIMENTAL PARASITOLOGY

Benzothiazinones Kill Mycobacterium tuberculosis by Blocking Arabinan Synthesis

(2009) V. Makarov et al.   SCIENCE

Mode of Action of Ranbezolid against Staphylococci and Structural Modeling Studies of Its Interaction with Ribosomes

(2008) V. Kalia et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY